Biome Grow Valuation

Is BIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIO?

Key metric: As BIO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BIO. This is calculated by dividing BIO's market cap by their current book value.
What is BIO's PB Ratio?
PB Ratio	-0.1x
Book	-CA$4.82m
Market Cap	CA$562.09k

BIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BIO's PB Ratio compare to its peers?

The above table shows the PB ratio for BIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.5x
HMPS Hempsana Holdings	1.1x	n/a	CA$591.3k
SUGR.H SugarBud Craft Growers	0.1x	n/a	CA$718.6k
MESC Lophos Holdings	0.6x	n/a	CA$858.6k
LOWL Lowell Farms	0.06x	n/a	CA$363.0k
BIO Biome Grow	n/a	n/a	CA$562.1k

Price-To-Book vs Peers: BIO has negative equity and a Price-To-Book Ratio (-0.1x) compared to the peer average (0.5x).

Price to Book Ratio vs Industry

How does BIO's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

10 Companies	Price / Book	Estimated Growth	Market Cap
AYR.A Ayr Wellness	0.1x	40.6%	US$79.88m
BZAM BZAM	0.08x	n/a	US$4.88m
AVNT Avant Brands	0.1x	n/a	US$4.17m
CPTR Captor Capital	0.07x	n/a	US$1.97m

10 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: BIO has negative equity and a Price-To-Book Ratio (-0.1x) compared to the Canadian Pharmaceuticals industry average (1.2x).

Price to Book Ratio vs Fair Ratio

What is BIO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BIO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medexus Pharmaceuticals

CA$58.7m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.38

12.8%

60.8%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$1.98

-17.2%

-65.9%

Cresco Labs

CA$525.4m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CA$1.67

-8.2%

-27.7%